SB 861 would repeal and replace Missouri’s existing section 191.1720 and add a new section defining terms related to gender transition and reproductive health care. The bill states that, unless clearly specified otherwise, “reproductive health care” does not include gender transition surgeries, cross-sex hormones, or puberty-blocking drugs used for gender transition. It also renames section 191.1720 as the “Missouri Save Adolescents from Experimentation (SAFE) Act” and provides detailed definitions for terms such as biological sex, gender transition, gender transition surgery, cross-sex hormones, and puberty-blocking drugs.
Substantively, the bill prohibits health care providers from knowingly performing gender transition surgery on anyone under 18 and from prescribing or administering cross-sex hormones or puberty-blocking drugs for gender transition to minors. It includes a grandfather clause for minors who were already receiving such treatment before August 28, 2023, and removes a prior sunset date that would have expired the hormone/puberty-blocker restrictions in 2027. The bill also creates civil liability for providers who violate the law, including a private right of action, extended limitations periods, rebuttable presumptions of harm in certain infertility cases, mandatory attorney’s fees, and enhanced damages. It further states that violations constitute unprofessional conduct subject to license revocation.
The bill would significantly affect Missouri health care law and professional discipline rules by restricting gender-affirming medical care for minors and by expanding potential civil exposure for providers. It also clarifies that the law does not apply to protected speech, certain services for individuals with disorders of sex development, treatment of complications caused by prior transition-related care, or emergency procedures necessary to prevent death or major bodily impairment. In addition, the bill would alter how “reproductive health care” is interpreted in state law by expressly excluding transition-related treatments from that category.
Because no committee transcripts or votes were provided, there is no recorded legislative debate or voting history in the materials. Based on the bill text alone, the measure appears strongly policy-driven and prescriptive, with a clear intent to restrict gender-affirming care for minors and to create enforcement mechanisms against providers. The absence of discussion records means the available context does not show any formal support, opposition, or amendments in committee.
The main point of contention inherent in the bill is the restriction of gender-affirming medical treatment for minors, especially the prohibition on puberty blockers and cross-sex hormones, which are commonly used in adolescent gender dysphoria treatment. Another likely point of dispute is the bill’s private right of action and enhanced damages provisions, which could be viewed as unusually punitive toward health care providers. Supporters would likely frame the bill as protecting children and limiting irreversible medical interventions, while opponents would likely argue it interferes with medical judgment, patient access, and transgender health care.
SB 861 would amend Missouri statutes by repealing and reenacting section 191.1720 and adding section 1.208, thereby changing how state law treats gender transition-related care. It would prohibit gender transition surgeries and the use of cross-sex hormones or puberty-blocking drugs for gender transition in minors, create disciplinary consequences for providers, and authorize civil lawsuits against providers who violate the restrictions. It also narrows the meaning of “reproductive health care” in state law so that it does not include gender transition procedures or medications.
No committee transcript or vote data were provided, so there is no documented legislative sentiment in the materials beyond the bill’s text. The bill itself reflects a strongly restrictive approach to gender-affirming care for minors and appears designed to deter such treatment through both professional discipline and civil liability. The caption and statutory findings suggest the sponsor’s intent is to frame the measure as child-protective, while the structure of the bill indicates it would likely be viewed as highly controversial by opponents of such restrictions.
The central controversy is whether the state should prohibit gender-affirming surgeries, hormones, and puberty blockers for minors, and whether those treatments should be treated as unlawful or unprofessional conduct. A second major point of contention is the bill’s enforcement scheme: it creates a private cause of action, extends the statute of limitations, presumes harm in some infertility cases, and allows uncapped damages and attorney’s fees, which critics may see as punitive and likely to chill medical practice. Supporters would likely emphasize protection of minors and limits on irreversible interventions, while opponents would likely focus on medical autonomy, access to care, and the impact on transgender youth and their families.